Gimatecan is under clinical development by Lee’s Pharmaceutical and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase II drugs for Epithelial Ovarian Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gimatecan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gimatecan overview

Gimatecan (LBQ-707, STI-481) is under development for the treatment of ovarian cancer, and small cell lung caner. The drug candidate is administered orally. It is a semi-synthetic lipophilic analogue of camptothecin. The drug candidate acts by targeting topoisomerase-I.

It was also under development for the treatment of solid tumors including advanced or metastatic pancreatic cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, non-small cell lung cancer (NSCLC), colorectal cancer, brain cancer, myelodysplastic syndrome, malignant glioma, refactory epithelial ovarian, fallopian and peritoneal cancers and soft tissue sarcoma.

Lee’s Pharmaceutical overview

Lee’s Pharmaceutical is a healthcare provider. The company develops, manufactures and markets novel therapies and contract research services. It offers products in the therapy areas of urology, cardiovascular oncology, pediatrics, dermatology, woman’s health, hematology, ophthalmology, dermatology, and obstetrics. The company’s products include bredinin tablets, dicoflor powder, episil oral gel, ferplex oral solution, rasilez tablets, teglutik oral suspension, cetraxal plus ear drops, intrarosa pessaries, lutrate depot, adasuve inhalation powder, teglutik oral suspension, natulan capsules, carnitine injection, readyfusor infusion pump, unidrox tablets, zanidip tablets and zingo needleless injection, among others. It offers products in the form of gel, injection, tablets, oral solutions and infusion systems. Its products are marketed in the regions of Hong Kong, China and Taiwan. The company works in partnership with other organizations for the development and distribution rights for products across the US, Japan and other regions in Europe. It operates through its manufacturing facility located at Hefei City, China. Lee’s Pharmaceutical is headquartered in Hong Kong.

For a complete picture of Gimatecan’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.